Nithya Balasubramanian, director of Sanford Bernstein said that she likes Cipla and Sun Pharmaceutical Industries in the pharma space.
Speaking in an interview to CNBC-TV18, she said, “Since the start of the year Cipla and Sun are the top picks, Cipla largely because we like the increasing visibility into their respiratory generics pipeline and the reason we like Sun because it has become more constructive about specialty portfolio. We thing the specialty portfolio can turn around and that is broadly why we like Sun Pharma.”
She also likes Lupin and has an outperform rating on the stock due to their complex generics pipeline in the US.
"I think Lupin is as invested in the complex respiratory generics pipeline as Cipla is,” she said.
We also like the fact that Lupin has built capabilities in the biosimilar space, Balasubramanian added.
For more details, watch the video